Pelago Biosciences offers 3 assay services for customers. In all cases an initial feasibility study is conducted on all and customers will be advised accordingly before an order is necessary.
Western blot based detection. Typically used for confirmation of target engagement of 1-5 compounds in a single cell type. Assay development phase 2-3 weeks, screening 1-2 weeks.
Plate based fluorescence detection format ideal for larger screening volumes. Assay development 8-12 weeks. Screening time dependant on volume.
Mass spectrometry detection of target engagement on up to 6000 proteins. No assay development phase required. Turnaround time 3-4 weeks.
Real world EC50 values for your compound in cells
CETSA® Classics and CETSA® HT employ antibody based detection, they are suitable for both lysates and cells, and can be applied to a wide variety of target classes. Critically the same assay can be applied to all standard cell lines used routinely, and with human tissue.
As no assay redevelopment is needed, compounds identified in early screening can be immediately investigated in patient samples to confirm preliminary results. Therefore, allowing the improved selection of suitable compounds before SAR occurs and indeed allowing a target to be validated in man before the clinical phase of project even starts.
Un-Biased Proteomic Profiling
CETSA® MS, is a mass spectrometry based derivation of CETSA®. It can analyse the systemic effect of compound on up to 6000 key proteins. Measuring not just the direct binding of compound to proteins but also the subsequent downstream consequences of such binding. This unbiased proteome wide profiling makes it ideal for target de-convolution, toxicity & biomarker studies.
Proteins of interested uncovered by CETSA MS are amenable to CETSA Classics and HT methods and therefore specific assays suitable for low-high throughput can be developed.
Contact us to discuss your project needs: firstname.lastname@example.org
For a quick review of CETSA® Classics, CETSA® HT and CETSA® MS, watch the video below.